SGS, a leading life sciences, pharmaceutical, clinical and bioanalytical contract solutions provider, announces the appointment of Dr Peter Hendrickx as Medical Director at the Clinical Pharmacology Unit (CPU) located within the Antwerp ZNA Stuivenberg hospital. He joins the existing medical team which currently comprises 10 full time Medical Doctors.
Dr Hendrickx, MD, graduated in 1996 from the University of Brussels and obtained an Informatics & Technology degree while serving as a Military Physician. After running his own consultancy company, he joined UCB (2010) as Global Medical Education Manager for movement and sleep disorders, then Bayer HealthCare (2012) as Medical Director for Belgium and Luxembourg, where he headed the Medical Department. Since 2015, he acted as Pharmacovigilance Regional Head for Europe and Canada at Bayer Pharma AG.
In his position at the CPU, he will be responsible for all SGS Early Phase Site medical activities and processes, including CPU and SGS Patient Sites in Belgium and Hungary, working closely with the existing SGS investigator physician and clinical pharmacology expert team.
“Peter’s expertise and experience will support the growing SGS early phase clinical trials and bring quality medical and pharmacology input in the protocol preparation phase. Peter will also facilitate the SGS phase I patient’s clinical pharmacology units’ network harmonisation and expansion,” commented Annick van Riel, CPU Director at SGS Clinical Research.
SGS provides clinical research and bioanalytical testing services with a specific focus on early stage development and biometrics. Delivering solutions in Europe and in the Americas, SGS offers clinical trial (phase I to IV) services encompassing drug development consultancy, clinical project management and monitoring, biometrics, PK/PD modelling and simulation, and regulatory and medical affairs services. SGS has its own CPU in Belgium including a human challenge testing facility and two phase I patient units based in Belgium and Hungary. SGS has a wealth of expertise in First-In-Human studies, viral challenge testing, biosimilars and complex PK/PD studies, with a therapeutic focus on infectious diseases, vaccines, and respiratory.
